Program
hydronidone
Also written as “Hydronidone capsules”, “Hydronidone” and “[¹⁴C]Hydronidone”.
Its studies are mostly in Liver Cirrhosis · Hepatitis B, Chronic · Renal Insufficiency, Chronic · Hepatitis B, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GNI Group | 143 open or running | phase 3since Oct 9, 2021 | Oct 9, 2019 | Dec 1, 2026phase 1 · NCT07262333 |
| Shanghai Genomics | 10 open or running | phase 2since Jun 26, 2015 | Jun 26, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2015First study: phase 2 study in Hepatitis B, ChronicNew to Shanghai GenomicsShanghai Genomics · NCT02499562 · 168 enrolled · China
- Oct 9, 2019GNI Group's first study: no phase study in HealthyNew to GNI GroupGNI Group · NCT04125056 · 40 enrolled · China
- Oct 10, 2019Phase 1 study in Hepatitis BGNI Group · NCT04123769 · 8 enrolled · China
- Nov 12, 2019Phase 1 study in Pharmacokinetics of HydronidoneGNI Group · NCT04162821 · 48 enrolled · China
- Oct 9, 2021Phase 3 study in Liver CirrhosisGNI Group · NCT05115942 · 248 enrolled · China
- Jun 7, 2023Phase 3 study in Liver CirrhosisGNI Group · NCT05905172 · 248 planned · China
- Nov 17, 20253 phase 1 studiesGNI Group · NCT07262346, NCT07262333, NCT07263152
- Jan 7, 20262 phase 3 studiesGNI Group · NCT07343778, NCT07412236
- Jan 16, 2026Phase 2 study in Chronic Hepatitis B With Hepatic FibrosisGNI Group · NCT07364448 · 411 enrolled · China
- Jan 30, 2026Phase 1 study in Liver CirrhosisGNI Group · NCT07394309 · 30 enrolled · China
- Feb 11, 2026Phase 2 study in Chronic Hepatitis B-related Liver FibrosisGNI Group · NCT07417553 · 67 enrolled · China
- Mar 10, 2026Phase 1 study in Chronic Hepatitis B-related Liver FibrosisGNI Group · NCT07471217 · 6 enrolled · China
Ahead
- Dec 1, 2026Primary completion: phase 1 study in Renal Insufficiency, ChronicGNI Group · NCT07262333
- Jun 20, 2028Primary completion: phase 3 study in Liver CirrhosisGNI Group · NCT05905172
- Dec 30, 2028Primary completion: phase 3 study in Liver CirrhosisGNI Group · NCT07412236
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07471217Chronic Hepatitis B-related Liver Fibrosis · China | 1 | Completed | GNI Group | May 6, 2026 | 6 |
| NCT07417553Chronic Hepatitis B-related Liver Fibrosis · China | 2 | Completed | GNI Group | Jul 27, 2026 | 67 |
| NCT07394309Liver Cirrhosis · China | 1 | Completed | GNI Group | May 11, 2026 | 30 |
| NCT07412236Liver Cirrhosis · China | 3 | Not yet recruiting | GNI Group | Dec 30, 2028 | 1,208 |
| NCT07364448Chronic Hepatitis B With Hepatic Fibrosis · China | 2 | Completed | GNI Group | Jun 22, 2026 | 411 |
| NCT07343778Chronic Hepatitis B With Hepatic Fibrosis · China | 3 | Completed | GNI Group | Jul 28, 2026 | 337 |
| NCT07263152Liver Cirrhosis · China | 1 | Completed | GNI Group | Feb 9, 2026 | 48 |
| NCT07262346Liver Cirrhosis · China | 1 | Completed | GNI Group | May 28, 2026 | 138 |
| NCT07262333Renal Insufficiency, Chronic · China | 1 | Recruiting | GNI Group | Dec 1, 2026 | 56 |
| NCT05905172Liver Cirrhosis · China | 3 | Recruiting | GNI Group | Jun 20, 2028 | 248 |
| NCT05115942Liver Cirrhosis · China | 3 | Completed | GNI Group | Oct 22, 2024 | 248 |
| NCT04162821Pharmacokinetics of Hydronidone · China | 1 | Completed | GNI Group | Nov 27, 2019 | 48 |
| NCT04123769Hepatitis B · China | 1 | Completed | GNI Group | Oct 9, 2020 | 8 |
| NCT04125056Healthy · China | – | Completed | GNI Group | Jan 23, 2019 | 40 |
| NCT02499562Hepatitis B, Chronic · China | 2 | Completed | Shanghai Genomics | Nov 20, 2020 | 168 |
How it is read
Names in the registry
- “Hydronidone capsules”, 7 entries
- “Hydronidone”, 4 entries
- “[¹⁴C]Hydronidone”, 1 entry
- “Hydronidone Capsules”, 1 entry
- “Hydronidone (270mg)”, 1 entry
Conditions, from the studies’ own filings
- Liver Cirrhosis, 6 studies
- Hepatitis B, Chronic, 5 studies
- Renal Insufficiency, Chronic, 1 study
- Hepatitis B, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.